Today: 9 June 2026
Lockheed Martin stock near $500 premarket as Venezuela shock and space-deal chatter refocus defense trade
5 January 2026
2 mins read

Lockheed Martin stock near $500 premarket as Venezuela shock and space-deal chatter refocus defense trade

NEW YORK, Jan 5, 2026, 05:43 ET — Premarket

  • Lockheed Martin was little changed in premarket trading, holding near $497 after Friday’s jump.
  • A Reuters report on L3Harris’ space propulsion stake sale put United Launch Alliance — co-owned by Lockheed — back on traders’ radar.
  • Investors are also watching Friday’s U.S. jobs report and Lockheed’s late-January earnings for the next directional cue.

Lockheed Martin (LMT.N) shares were little changed at $497.07 in premarket trading on Monday, holding near last session’s close after the stock rose about 2.8% on Friday.

Defense names drew fresh attention after U.S. President Donald Trump said the United States captured Venezuelan President Nicolas Maduro after strikes over the weekend, a flashpoint investors said could reshape how markets price geopolitical risk. “We’re being reminded that geopolitical risks are much larger than some number cast on imports,” said Vishnu Varathan, head of macro research for Asia ex-Japan at Mizuho Securities in Singapore. Reuters

Separately, Reuters reported L3Harris Technologies is in advanced talks to sell a 60% stake in its Commercial Aviation Solutions business to private equity firm AE Industrial Partners at an enterprise value of about $845 million. Enterprise value is a common deal yardstick that includes debt, giving a fuller picture of what a buyer is paying.

The portfolio includes the RL-10 rocket engine used in United Launch Alliance’s Vulcan launcher, Reuters said. ULA is a joint venture owned by Boeing and Lockheed, and the report said the business also has ties to the Pentagon’s emerging “Golden Dome” missile-defense effort — a plan for a layered shield designed to detect and intercept missiles. Reuters

For Lockheed shareholders, the swirl matters because space and missile-defense programs sit at the intersection of geopolitics, budget priorities and industrial capacity. Any shift in supply chains or funding can ripple across primes and their partners.

Technically, traders have been watching the stock’s approach to $500, a round-number level that can act as a psychological hurdle. Barchart data put the first resistance point near $503.97 and first support around $483.35, with the 52-week high at $516.00.

The next company catalyst is earnings. TipRanks lists Lockheed’s next report for Jan. 27, before the open, with an EPS forecast of about $6.49 for the quarter.

Macro events may set the tone before then, starting with the U.S. employment report for December scheduled for Jan. 9 and the December consumer price index due Jan. 13. The Federal Reserve’s next policy meeting is set for Jan. 27-28.

Lockheed competes with peers such as RTX and Northrop Grumman across missiles, sensors and other defense programs, while its ULA partnership links it to developments in the U.S. launch market. Moves across the group often track shifts in perceived geopolitical risk and expectations for defense budgets.

But the bid for defense stocks can fade if markets decide the Venezuela shock stays contained or if budget politics swing back toward restraint. Deal headlines can also disappoint: a slower timeline or changed terms around the L3Harris asset sale would likely cool some of the near-term enthusiasm.

Stock Market Today

  • NOV Stock Up 32% in Six Months: Key Factors and Investor Outlook
    June 9, 2026, 10:21 AM EDT. NOV Inc. shares have surged 31.5% over six months, outpacing the Mechanical and Equipment Oil and Gas sub-industry and broader energy sector. The company benefits from strong offshore equipment demand, driven by subsea flexible pipe growth and offshore projects through 2028. NOV's focus on automation and cost reduction, including headcount and facility cuts, supports operational efficiency. Management anticipates a multi-year upcycle in capital equipment spending due to energy security and renewed offshore investment, bolstering demand. With a solid backlog and positive 2026 earnings outlook, NOV's positioning suggests potential for continued gains, raising questions for investors on whether to hold or sell amid market shifts.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks
Previous Story

BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks

Applied Digital (APLD) stock jumps 6% as earnings loom and ChronoScale deal stays in focus
Next Story

Applied Digital (APLD) stock jumps 6% as earnings loom and ChronoScale deal stays in focus

Go toTop